CTOs on the Move

Oxford Pharmaceutical Resources

www.oxfordpharm.com

 
Oxford Pharmaceutical Resources is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Medi Home Care Inc

Medi Home Care Inc is a Elizabeth City, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biosensors International-Usa

Biosensors International-Usa is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novarix

Novarix is a collaborative medical device development company based near Oxford, UK and Raleigh, North Carolina, USA, delivering innovative new products in the field of venepuncture and cannulation to the worldwide healthcare sector. Novarix are proud to bring to market the IV-eye® – a portable, near infrared (NIR) vein imaging device which demonstrates the company ethos of practicality, simplicity and performance for both healthcare professionals and patients. The product idea came from a nursing perspective and has been developed in consultation with medical professionals in the UK and Denmark and with assistance from the biomedical engineering departments of Oxford University and University College London.

Guerbet

Guerbet is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Motif Neurotech

Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.